Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Remedy Pharmaceuticals, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT03954041
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Scottsdale Healthcare Hospitals d/b/a HonorHealth, Scottsdale, Arizona, United States
🇺🇸University of Arizona Medical Center, Tucson, Arizona, United States
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Remedy Pharmaceuticals, Inc.
- Target Recruit Count
- 535
- Registration Number
- NCT02864953
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Arizona Board of Regents, University of Arizona, Tucson, Arizona, United States
🇺🇸Stanford Stroke Center, Palo Alto, California, United States
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
- Conditions
- Ischemic StrokeMalignant Edema
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-02-18
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Remedy Pharmaceuticals, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT01794182
- Locations
- 🇺🇸
University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Remedy Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01454154
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸University of Maryland Medical Center, Shock Trauma Center, Baltimore, Maryland, United States
🇺🇸UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States
Glyburide Advantage in Malignant Edema and Stroke Pilot
- First Posted Date
- 2010-12-31
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Remedy Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01268683
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States